Drug Profile

SENTI 202

Alternative Names: SENTI-202

Latest Information Update: 27 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Senti Biosciences
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Haematological malignancies
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Haematological malignancies

Most Recent Events

15 Jul 2026 Senti Biosciences Holdings and NewCo entered into a licensing agreement to develop SENTI 202
15 Jul 2026 Senti Biosciences plans to file BLA for SENTI 202 to the US FDA
14 May 2026 Senti Biosciences completes Type B Initial Comprehensive Multidisciplinary RMAT meeting with the US FDA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com